AGIO Key Statistics, Chart & Performance
The current stock price of AGIO is 29.2 USD. In the past month the price decreased by -32.38%. In the past year, price decreased by -50.83%.
AGIO Latest News, Press Relases and Analysis
AGIO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.1 | 402.43B | ||
| AMGN | AMGEN INC | 15.8 | 186.02B | ||
| GILD | GILEAD SCIENCES INC | 15.37 | 156.13B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.98 | 110.02B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.33 | 82.00B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 884.76 | 59.61B | ||
| INSM | INSMED INC | N/A | 44.31B | ||
| NTRA | NATERA INC | N/A | 32.96B | ||
| BIIB | BIOGEN INC | 10.88 | 26.71B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.42 | 20.93B | ||
| INCY | INCYTE CORP | 16.27 | 20.51B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.22B |
Related stock screener links
About AGIO
Company Profile
Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. The company is headquartered in Cambridge, Massachusetts and currently employs 486 full-time employees. The company went IPO on 2013-07-24. The firm is focused on developing and delivering transformative therapies for patients living with rare diseases. The company markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its portfolio, PYRUKYND (mitapivat), is an activator of both wild-type and mutant pyruvate kinase, or PK, enzymes for the potential treatment of hemolytic anemias. The company is also developing tebapivat, a novel PK activator, for the potential treatment of lower-risk myelodysplastic syndromes, or LR MDS, and hemolytic anemias; AG-181, its phenylalanine hydroxylase, or PAH, stabilizer for the potential treatment of phenylketonuria, or PKU; and AG-236, an siRNA in-licensed from Alnylam Pharmaceuticals, Inc., targeting the transmembrane serine protease 6, or TMPRSS6 gene for the potential treatment of polycythemia vera, or PV.
Company Info
AGIOS PHARMACEUTICALS INC
88 Sidney Street
Cambridge MASSACHUSETTS 02139 US
CEO: Jacqualyn A. Fouse
Employees: 486
Phone: 16176498600
AGIOS PHARMACEUTICALS INC / AGIO FAQ
What does AGIOS PHARMACEUTICALS INC do?
Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. The company is headquartered in Cambridge, Massachusetts and currently employs 486 full-time employees. The company went IPO on 2013-07-24. The firm is focused on developing and delivering transformative therapies for patients living with rare diseases. The company markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its portfolio, PYRUKYND (mitapivat), is an activator of both wild-type and mutant pyruvate kinase, or PK, enzymes for the potential treatment of hemolytic anemias. The company is also developing tebapivat, a novel PK activator, for the potential treatment of lower-risk myelodysplastic syndromes, or LR MDS, and hemolytic anemias; AG-181, its phenylalanine hydroxylase, or PAH, stabilizer for the potential treatment of phenylketonuria, or PKU; and AG-236, an siRNA in-licensed from Alnylam Pharmaceuticals, Inc., targeting the transmembrane serine protease 6, or TMPRSS6 gene for the potential treatment of polycythemia vera, or PV.
What is the current price of AGIO stock?
The current stock price of AGIO is 29.2 USD. The price increased by 0.55% in the last trading session.
What is the dividend status of AGIOS PHARMACEUTICALS INC?
AGIO does not pay a dividend.
How is the ChartMill rating for AGIOS PHARMACEUTICALS INC?
AGIO has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What is the Price/Earnings (PE) ratio of AGIOS PHARMACEUTICALS INC (AGIO)?
AGIOS PHARMACEUTICALS INC (AGIO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-6.7).
What is the expected growth for AGIO stock?
The Revenue of AGIOS PHARMACEUTICALS INC (AGIO) is expected to grow by 27.91% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
AGIO Technical Analysis
AGIO Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to AGIO. While AGIO has a great health rating, there are worries on its profitability.
AGIO Financial Highlights
Over the last trailing twelve months AGIO reported a non-GAAP Earnings per Share(EPS) of -6.7. The EPS increased by 7.92% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -28.96% | ||
| ROE | -31.24% | ||
| Debt/Equity | 0 |
AGIO Forecast & Estimates
14 analysts have analysed AGIO and the average price target is 50.39 USD. This implies a price increase of 72.56% is expected in the next year compared to the current price of 29.2.
For the next year, analysts expect an EPS growth of -6.2% and a revenue growth 27.91% for AGIO